Popular drug slows early-stage lung cancer


AstraZeneca’s top-selling drug Tagrisso has been shown to hold back a certain type of lung cancer when diagnosed at an early stage, the British drugmaker said on Thursday, potentially adding billions to its sales potential. The trial results presented at the virtual American Society of Clinical Oncology (ASCO) conference this week may open up a treatment option to patients diagnosed early enough for the tumour to be surgically removed, and who have a mutation of the so-called EGFR gene, it said.